| Name | Title | Contact Details |
|---|
Annovis Bio is developing a drug for Alzheimers Disease, Parkinsons Disease and other neurodegenerative diseases that inhibits more than one neurotoxic protein and, thereby, improves the information highway of the nerve cell, known as axonal transport.
MBX Biosciences is a preclinical-stage biotechnology company using validated molecular targets to create medicines for rare endocrine diseases where current therapies are inadequate.
Waste Reduction is a Indianapolis, IN-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Aptinyx Inc. (formerly Naurex Inc.) is a biopharmaceutical company focused on discovery and development of transformative therapies for challenging disorders of the brain and nervous system. Aptinyx has a proven platform for discovering compounds that enhance synaptic plasticity, or strengthen the network for neural cell communication. Molecules discovered by Aptinyx achieve this through a novel mechanism that modulates NMDA receptors, resulting in drugs that are both highly effective and well tolerated. This mechanism has applicability across a number of brain and nervous system disorders. Aptinyx is rapidly advancing promising drug candidates into clinical development for indications with high unmet medical need.
Agenta Biotechnologies is a Birmingham, AL-based company in the Healthcare, Pharmaceuticals, and Biotech sector.